Leveraging our in vivo drug discovery platform, databases, machine learning, and simple animal models, we focus on unlocking Mechanism of Actions for rare and complex disorders with unmet needs.
Modelis’ pipeline is based on ground-breaking research by Dr. Alex Parker (co-founder and Chief Scientific Officer at Modelis) and colleagues which led to the discovery of a new therapeutic compound for Amyotrophic Lateral Sclerosis (ALS).
In short, more than 4,000 approved compounds were tested against motor defects described in ALS-like mutant worms. Interestingly, several of these molecules belonging to the neuroleptic family were found to have a beneficial effect on these motor defects. A short list of fifteen of these neuroleptics were validated on ALS genetic avatars and Pimozide stood out as the more promising candidate. Pimozide is an Food and Drug Administration (FDA)- approved drug that was originally used to treat schizophrenia. Finally, electrophysiological studies in mouse models confirmed the beneficial effects of Pimozide when treating motor defects caused by ALS. Following these results, a proof-of-concept clinical trial was performed suggesting an apparent stabilization of motor power deterioration. A ten-centre randomized controlled clinical trial examining the effect of 6 months of pimozide therapy in patients with ALS is underway (ID NCT03272503) and is expected to be completed by the end 2020.
THE ADVANTAGES OF WORKING WITH US
We mimic an individuals genetic mutation so that we can rapidly test multiple treatments that are customized to the individual. Modelis works alongside you each step of the way making you a key part of our research model.
Taking advantage of simple animal models that cost up to 10x less than classical mammals, our drug discovery pipeline is time and money-efficient.
Modelis’ strategy has successfully found therapeutic solutions and a novel mechanism of action when more classical approaches have failed. Read about our most recent success here.
We do drug discovery differently.
We are currently advancing rapid-development programs to treat seven rare diseases, four backed by patient partners.
Our combined resources with best-in-class partners and collaborators drive research with meaningful impact.
OUR ETHICS AND ANIMAL CARE
At Modelis, we want to make a difference and are translating this into value for patients. Our main goal is to make an impact in our patients journey and quality of life. We are less concerned about publishing in top research journals.
We are driven and focused on the individuals health. Our team of passionate scientists are deploying efforts toward this aim and all decisions are prioritizing public wellness. To reach its mission and vision, we rely on strong values: Passion, Expertise and Innovation.
As a for-profit organization, we will remain transparent on our industrial partnerships and financial position.
Modelis is promoting local economies and is contributing to the rise of the thriving technological innovation culture in Montreal, Quebec, and all of Canada.
©2022 Modelis inc. All rights reserved